FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210361884> ?p ?o ?g. }

• W4210361884 endingPage "1665" @default.
• W4210361884 startingPage "1665" @default.
• W4210361884 abstract "Triple-negative breast cancer (TNBC) is associated with high recurrence rates, high incidence of distant metastases, and poor overall survival (OS). Taxane and anthracycline-containing chemotherapy (CT) is currently the main systemic treatment option for TNBC, while platinum-based chemotherapy showed promising results in the neoadjuvant and metastatic settings. An early arising of intrinsic or acquired CT resistance is common and represents the main hurdle for successful TNBC treatment. Numerous mechanisms were uncovered that can lead to the development of chemoresistance. These include cancer stem cells (CSCs) induction after neoadjuvant chemotherapy (NACT), ATP-binding cassette (ABC) transporters, hypoxia and avoidance of apoptosis, single factors such as tyrosine kinase receptors (EGFR, IGFR1), a disintegrin and metalloproteinase 10 (ADAM10), and a few pathological molecular pathways. Some biomarkers capable of predicting resistance to specific chemotherapeutic agents were identified and are expected to be validated in future studies for a more accurate selection of drugs to be employed and for a more tailored approach, both in neoadjuvant and advanced settings. Recently, based on specific biomarkers, some therapies were tailored to TNBC subsets and became available in clinical practice: olaparib and talazoparib for BRCA1/2 germline mutation carriers larotrectinib and entrectinib for neurotrophic tropomyosin receptor kinase (NTRK) gene fusion carriers, and anti-trophoblast cell surface antigen 2 (Trop2) antibody drug conjugate therapy for heavily pretreated metastatic TNBC (mTNBC). Further therapies targeting some pathologic molecular pathways, apoptosis, miRNAS, epidermal growth factor receptor (EGFR), insulin growth factor 1 receptor (IGF-1R), and androgen receptor (AR) are under investigation. Among them, phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and EGFR inhibitors as well as antiandrogens showed promising results and are under evaluation in Phase II/III clinical trials. Emerging therapies allow to select specific antiblastics that alone or by integrating the conventional therapeutic approach may overcome/hinder chemoresistance." @default.
• W4210361884 created "2022-02-08" @default.
• W4210361884 creator A5021869592 @default.
• W4210361884 creator A5022888812 @default.
• W4210361884 creator A5023003861 @default.
• W4210361884 creator A5040416185 @default.
• W4210361884 creator A5056157710 @default.
• W4210361884 creator A5078313635 @default.
• W4210361884 date "2022-01-31" @default.
• W4210361884 modified "2023-10-02" @default.
• W4210361884 title "Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC" @default.
• W4210361884 cites W1058934875 @default.
• W4210361884 cites W1483167997 @default.
• W4210361884 cites W1483980835 @default.
• W4210361884 cites W17597684 @default.
• W4210361884 cites W1783165260 @default.
• W4210361884 cites W1791486331 @default.
• W4210361884 cites W1879042627 @default.
• W4210361884 cites W1931183350 @default.
• W4210361884 cites W1933892142 @default.
• W4210361884 cites W1942447546 @default.
• W4210361884 cites W1963083447 @default.
• W4210361884 cites W1966399801 @default.
• W4210361884 cites W1971270230 @default.
• W4210361884 cites W1974074221 @default.
• W4210361884 cites W1974472781 @default.
• W4210361884 cites W1975401903 @default.
• W4210361884 cites W1979250236 @default.
• W4210361884 cites W1988055795 @default.
• W4210361884 cites W1988398656 @default.
• W4210361884 cites W1990983360 @default.
• W4210361884 cites W1994756768 @default.
• W4210361884 cites W1999251458 @default.
• W4210361884 cites W2000315116 @default.
• W4210361884 cites W2000610587 @default.
• W4210361884 cites W2005867761 @default.
• W4210361884 cites W2005997013 @default.
• W4210361884 cites W2006122819 @default.
• W4210361884 cites W2008870230 @default.
• W4210361884 cites W2008947700 @default.
• W4210361884 cites W2017256144 @default.
• W4210361884 cites W2025021524 @default.
• W4210361884 cites W2026691651 @default.
• W4210361884 cites W2032323336 @default.
• W4210361884 cites W2033346155 @default.
• W4210361884 cites W2035921832 @default.
• W4210361884 cites W2038329478 @default.
• W4210361884 cites W2041809484 @default.
• W4210361884 cites W2043409879 @default.
• W4210361884 cites W2044149912 @default.
• W4210361884 cites W2049126730 @default.
• W4210361884 cites W2050732886 @default.
• W4210361884 cites W2052623429 @default.
• W4210361884 cites W2054062143 @default.
• W4210361884 cites W2055498399 @default.
• W4210361884 cites W2057441424 @default.
• W4210361884 cites W2065938303 @default.
• W4210361884 cites W2067533256 @default.
• W4210361884 cites W2074993856 @default.
• W4210361884 cites W2076203883 @default.
• W4210361884 cites W2083087817 @default.
• W4210361884 cites W2096027508 @default.
• W4210361884 cites W2098804778 @default.
• W4210361884 cites W2104024752 @default.
• W4210361884 cites W2104453868 @default.
• W4210361884 cites W2106292881 @default.
• W4210361884 cites W2107554353 @default.
• W4210361884 cites W2109205642 @default.
• W4210361884 cites W2109772731 @default.
• W4210361884 cites W2113637823 @default.
• W4210361884 cites W2114505219 @default.
• W4210361884 cites W2114639059 @default.
• W4210361884 cites W2115504447 @default.
• W4210361884 cites W2116760308 @default.
• W4210361884 cites W2118605519 @default.
• W4210361884 cites W2124156632 @default.
• W4210361884 cites W2127438438 @default.
• W4210361884 cites W2127716534 @default.
• W4210361884 cites W2130811843 @default.
• W4210361884 cites W2131994307 @default.
• W4210361884 cites W2134539328 @default.
• W4210361884 cites W2136178883 @default.
• W4210361884 cites W2137463275 @default.
• W4210361884 cites W2139648620 @default.
• W4210361884 cites W2144198445 @default.
• W4210361884 cites W2145352614 @default.
• W4210361884 cites W2148678536 @default.
• W4210361884 cites W2148812205 @default.
• W4210361884 cites W2148925386 @default.
• W4210361884 cites W2152276633 @default.
• W4210361884 cites W2152979067 @default.
• W4210361884 cites W2153206149 @default.
• W4210361884 cites W2153769134 @default.
• W4210361884 cites W2155518897 @default.
• W4210361884 cites W2157285286 @default.
• W4210361884 cites W2161382947 @default.
• W4210361884 cites W2169727232 @default.
• W4210361884 cites W2170602872 @default.

• next